Industry webinar:
Enhancing Cardiotoxicity Assessment
with Holotomography in Human iPSC-CMs
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
October 22nd, 2024
Join our exclusive industry webinar!
Register here!
Different Timezone? Click here
1 – Click on “Convert to other timezone”
2 – Click on “Select timezone”
3 – Choose your timezone from the dropdown menu.
4 – Choose the time you want to attend
5- Fill the rest of your details and click “Register”.
Agenda
Ambroise Garry, the Group Head for Global Investigative Toxicology within preclinical safety at Sanofi will present some of the work his team has carried out studying cardiotoxicity in human iPSC-derived cardiomyocytes. He will discuss data acquired using holotomography to study the cell responses to established drugs known primarily for inducing phospholipidosis, which may also trigger cell death.
Cardiotoxicity is a significant cause of clinical trials failure in new drug candidates, contributing to the overall failure rate of around 90% for all drug candidates. Phenotypic screening provided by technologies such as high-content live cell imaging could provide an opportunity to catch failures at an earlier, in vitro stage, and increase the translatability of drugs to clinic.
Topics covered:
- Cardiovascular derisking with label-free live cell imaging
- Drug-induced phospholipidosis
- Label-free quantification of lipid droplets, lamellar bodies, and cytotoxicity evaluation in cells
- IC50 calculation from live cell imaging
- Doxorubicin-induced cardiotoxicity
This event will only be available online at the following times:
22nd October at 4 pm CEST/ 10 am EDT / 7 am PDT
22nd October at 10 pm CEST/ 4 pm EDT / 1 pm PDT
23rd October at 1 am CEST/ 22nd October 7 pm EDT / 22nd October 4 pm PDT
Speakers
Hope Amos
Scientific Communication Specialist, Nanolive
Ambroise Garry
Group Head for Global Investigative Toxicology, Sanofi